PRECLINICAL ALZHEIMER'S DISEASE
Clinical trials for PRECLINICAL ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new PRECLINICAL ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for PRECLINICAL ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a vaccine stop Alzheimer's before it starts?
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage study tests a new vaccine called AV-1980R in 48 older adults (ages 65-80) who have early signs of Alzheimer's but no memory problems. The vaccine aims to train the immune system to target a harmful protein in the brain. The main goal is to check if the vaccine is…
Matched conditions: PRECLINICAL ALZHEIMER'S DISEASE
Phase: PHASE1 • Sponsor: Institute for Molecular Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 04:08 UTC
-
Major trial takes on Alzheimer's tau tangles with multiple drugs
Disease control Not yet recruitingThis study tests whether drugs that target tau protein, alone or with another drug (donanemab), can slow Alzheimer's in people aged 50–80 with very early symptoms. About 900 participants will receive different treatments or placebos over 30 months, with regular brain scans and me…
Matched conditions: PRECLINICAL ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could a tau vaccine slow Alzheimer's? new trial aims to find out.
Disease control Not yet recruitingThis phase 2 trial tests whether AADvac1, a vaccine-like therapy targeting tau protein, alone or with donanemab, can reduce tau buildup in the brain and slow Alzheimer's progression. About 450 adults aged 50-80 with early Alzheimer's will participate. The goal is to see if this a…
Matched conditions: PRECLINICAL ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Paul S. Aisen • Aim: Disease control
Last updated May 11, 2026 20:40 UTC